ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11. ORION-10 completion marks successful conclusion of pivotal Phase 3 LDL-C lowering studies of inclisiran. Detailed data from ORION-10 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions in Philadelphia...
Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo....
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral mucositis....
Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days....
Fitbit users in Belgium, the Netherlands, Ireland and the United Kingdom can use FibriCheck to help detect heart rhythm irregularities like Atrial Fibrillation ...
The following slide deck was published by Medtronic $MDT in conjunction with their Robotic-Assisted Surgery (RAS) Investor on September 24, 2019....
Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced the initial surgeries of the PROLIFT Lateral Expandable Spacer System....
Biomechanically, the Luna device performed better in reducing intervertebral motion than the Anterior Lumbar Interbody Fusion (ALIF) control cage ...
U.S. Approval of the First and Only Nitinol Atherectomy Guide Wire Expands Company’s Portfolio of Products Targeting Complex Coronary Disease ...